Related Experiment Video
Updated: Dec 3, 2025
05:27
Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells
Published on: June 16, 2023
2.0K
Long non‑coding RNA PCAT6 promotes the development of osteosarcoma by increasing MDM2 expression
Xiliang Guan1, Yufen Xu2, Jufen Zheng3
1Department of Orthopaedic Surgery, People's Hospital of Rizhao, Rizhao, Shandong 276826, P.R. China.
Oncology Reports
|October 30, 2020
Summary
Long non-coding RNA PCAT6 accelerates osteosarcoma progression by upregulating MDM2 and downregulating P53 and P21. This study reveals PCAT6 as a potential therapeutic target for osteosarcoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Osteosarcoma is a serious bone cancer.
- Long non-coding RNA PCAT6 (lncRNA PCAT6) is implicated in various cancers.
- MDM2 exacerbates tumors by inhibiting P53.
Purpose of the Study:
- To investigate the role of lncRNA PCAT6 in osteosarcoma proliferation and metastasis.
- To explore the regulatory mechanism involving MDM2 and P53.
Main Methods:
- Overexpression of lncRNA PCAT6 in osteosarcoma cells.
- Cell Counting Kit-8, wound healing, and Transwell assays for proliferation, migration, and invasion.
- Western blotting for MDM2, P53, and P21 expression.
- MDM2 knockdown experiments.
Main Results:
- Overexpression of lncRNA PCAT6 increased osteosarcoma cell proliferation, migration, and invasion.
- lncRNA PCAT6 upregulated MDM2 and downregulated P53 and P21.
- MDM2 knockdown inhibited cell proliferation, migration, and invasion, rescuing P53 and P21 levels.
Conclusions:
- lncRNA PCAT6 promotes osteosarcoma progression by upregulating MDM2 and suppressing P53 and P21.
- Targeting lncRNA PCAT6 or MDM2 may offer therapeutic strategies for osteosarcoma.
Keywords:
osteosarcomalong non-coding RNA prostate cancer-associated transcript 6E3 ubiquitin-protein ligase Mdm2P53proliferationMore Related Videos
Related Concept Videos
02:23Abnormal Proliferation
4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
03:03mTOR Signaling and Cancer Progression
4.3K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.3K
02:39lncRNA - Long Non-coding RNAs
9.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.5K
01:22PI3K/mTOR/AKT Signaling Pathway
4.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.9K